GLP-1 medications have transformed how many people approach weight management, and their reach now extends into the global food supply chain. A recent analysis from Brand Finance shows that these treatments place roughly $73 billion in food brand value at risk worldwide. The findings single out several well-known snack names as particularly exposed to shifting consumer habits. ([1])
Brands Facing the Greatest Pressure
PepsiCo’s Lay’s stands out as the most vulnerable product line according to the report. Other household names share similar exposure, including Doritos, Cheetos, Hershey’s, Kellogg’s, and Reese’s. These products often rely on indulgent, high-calorie profiles that align less closely with reduced appetites reported by many GLP-1 users.
The concentration of risk among salty and sweet snacks reflects broader patterns in how these medications work. Users frequently describe smaller portion sizes and fewer between-meal cravings. Brand Finance’s assessment translates those behavioral changes into measurable financial exposure for the companies behind the products.
Why the Numbers Matter Now
GLP-1 drugs such as semaglutide have moved from niche prescriptions to widespread use in recent years. Their impact on daily calorie intake can be substantial, especially for items positioned as treats or quick snacks. The $73 billion figure captures the potential erosion in brand equity if consumption trends continue or accelerate.
Food companies have already begun adjusting recipes and marketing in response to health-conscious consumers. The new data adds urgency by quantifying how quickly preferences may shift when medication supports sustained weight reduction. Investors and retailers are watching closely for early signs of volume declines in these categories.
Broader Effects on the Industry
Snack manufacturers face a dual challenge: maintaining relevance while many shoppers seek lighter options. Some brands may explore smaller package sizes, lower-calorie reformulations, or entirely new product lines. Others could emphasize functional benefits or portion control to retain shelf space.
Retailers, meanwhile, may rebalance inventory toward items perceived as more compatible with medication-assisted eating patterns. The report does not predict the end of any single brand, yet it underscores how medical advances can ripple through unrelated sectors with surprising speed.
Looking Ahead
Consumer tastes have never remained static, and the current wave of GLP-1 adoption represents one more variable in a long history of dietary change. Companies that adapt thoughtfully may limit downside, while those slow to respond could see lasting effects on valuation. The Brand Finance analysis serves as an early indicator rather than a final verdict.
Ultimately, the intersection of medicine and food culture continues to evolve. Observers will track sales data and brand performance in the quarters ahead to see how the $73 billion exposure plays out in practice.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.